


Please amend page 20, line 1 as follows:

Claims What is claimed is:


This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Original) A peptide of the amino acid sequence of formula (I)



or formula (II)



wherein

X¹ is an amino acid selected from the group Ser, His, Thr, Ala, Gln, Phe, Gly and Ile

X² is an amino acid selected from the group Tyr, Arg and Phe

X³ is an amino acid selected from the group Tyr, Ser, Asn, Glu, Asp and Thr

X⁴ is an amino acid selected from the group Ser, Ala, Gly, Asp and Phe

X⁵ is an amino acid selected from the group Asp and Ser,

X⁷ is an amino acid selected from the group Thr, Val, Met, Ser, Trp, Tyr, Leu and Ala

X⁸ is an amino acid selected from the group Tyr, Phe and Leu

X⁹ is an amino acid selected from the group Asp, Ser and Glu


Z¹ represent an amino acid residue capable of forming a disulphide bond, preferably a cysteine or a homocysteine residue, or a residue capable of forming a thioether preferably the residue is Q-C(=O) wherein Q represents -(CH₂)_n or -(CH₂)_n-C₆H₄ where n represents a positive integer 1 to 10 or is absent and

Z² represent an amino acid residue capable of forming a disulphide bond, preferably a cysteine or a homocysteine residue or is absent

Y¹ represents 1-10 amino acids or is absent

or pharmaceutically acceptable salts thereof.

2. (Original) A peptide according to claim 1 of the amino acid sequence
Cys-Ser-Tyr-Tyr-Ser-Asp-Gly-Val-Tyr-Asp-Cys, (SEQ ID NO 1),
Cys-His-Tyr-Ser-Ser-Asp-Gly-Thr-Tyr-Asp-Cys, (SEQ ID NO 2),
Cys-Thr-Tyr-Asn-Gly-Asp-Gly-Ser-Phe-Asp-Cys, (SEQ ID NO 3),
Cys-Ala-Tyr-Glu-Ala-Asp-Gly-Trp-Phe-Asp-Cys, (SEQ ID NO 4),
Cys-Ser-Tyr-Ser-Ala-Asp-Gly-Thr-Leu-Asp-Cys, (SEQ ID NO 5),
Cys-Gln-Tyr-Asp-Ser-Ser-Gly-Met-Tyr-Asp-Cys, (SEQ ID NO 6),
Cys-Phe-Phe-Asp-Ser-Ser-Gly-Tyr-Phe-Asp-Cys, (SEQ ID NO 7),
Cys-Thr-Tyr-Ser-Ala-Asp-Gly-Leu-Tyr-Asp-Cys, (SEQ ID NO 8),
Cys-His-Phe-Asp-Gly-Asp-Gly-Ser-Tyr-Asp-Cys, (SEQ ID NO 9),
Cys-Thr-Tyr-Glu-Pro-Ser-Gly-Met-Tyr-Asp-Cys, (SEQ ID NO 10),
Cys-Gln-Tyr-Thr-Ala-Asp-Gly-Ala-Phe-Asp-Cys, (SEQ ID NO 11),
Cys-Ile-Tyr-Glu-Ser-Asp-Gly-Met-Phe-Ser-Cys, (SEQ ID NO 12),
Cys-Gly-Arg-Ser-Asp-Gly-Thr-Trp-Tyr-Glu-Cys, (SEQ ID NO 13) or
Cys-Ser-Tyr-Tyr-Ala-Asp-Gly-Met-Tyr-Ser-Cys, (SEQ ID NO 14).
3. (Currently amended) A targetable diagnostic and/ or therapeutically active agent of
formula (III)
V-L-Z Formula (III)
wherein the vector V is a peptide according to claim 1–2
L represents a bond, a spacer or a linker and
Z represents an antineoplastic agent, a reporter moiety or a group that optionally can
carry an imaging moiety M.
4. (Original) An agent as claimed in claim 3 where Z is a chelating agent of
Formula IV



(IV)

where:

each R¹, R², R³ and R⁴ is independently an R group;

each R group is independently H or C₁₋₁₀ alkyl, C₃₋₁₀ alkylaryl, C₂₋₁₀ alkoxyalkyl, C₁₋₁₀ hydroxyalkyl, C₁₋₁₀ alkylamine, C₁₋₁₀ fluoroalkyl, or 2 or more R groups, together with the atoms to which they are attached form a carbocyclic, heterocyclic, saturated or unsaturated ring.

5. (Currently amended) An agent as claimed in ~~any of the previous claims 3 to 4~~ claim 3 wherein Z comprises a reporter moiety, M wherein the reporter moiety M comprises metal radionuclides, paramagnetic metal ions, fluorescent metal ions, heavy metal ions or cluster ions.

6. (Original) An agent as claimed in claim 5 wherein the reporter moiety M comprises ⁹⁰Y, ^{99m}Tc, ¹¹¹In, ⁴⁷Sc, ⁶⁷Ga, ⁵¹Cr, ^{177m}Sn, ⁶⁷Cu, ¹⁶⁷Tm, ⁹⁷Ru, ¹⁸⁸Re, ¹⁷⁷Lu, ¹⁹⁹Au, ²⁰³Pb, ¹⁴¹Ce or ¹⁸F.

7. (Currently amended) An agent as claimed in ~~claims 3 to 6~~ claim 3 where each reporter (Z) can carry a multiplicity of vectors V.

8. (Original) An agent as claimed in claim 3 where the antineoplastic agent Z represent cyclophosphamide, chloroambucil, busulphan, methotrexate, cytarabine, fluorouracil, vinblastine, paclitaxel, doxorubicin, daunorubicin, etoposide, teniposide, cisplatin, amsacrine or docetaxel.
9. (original) A pharmaceutical composition comprising an effective amount of a compound of general Formula (III) or a salt thereof, together with one or more pharmaceutically acceptable adjuvants, excipients or diluents for use in enhancing image contrast in *in vivo* imaging or for treatment of a disease.
10. (Currently amended) A method of generating enhanced images of a human or animal body previously administered with a contrast agent composition comprising a compound as claimed in ~~claims 3 to 7~~ claim 3, which method comprises generating an image of at least part of said body.